← Home
Bristol Myers Squibb 
Pharma / Pharma
Press Releases
| Date | Press release |
|---|---|
| 2025-04-24 06:59:00 | Bristol Myers Squibb Reports First Quarter Financial Results For 2025 Princeton, n.j.--(business wire)--bristol myers squibb reports first quarter financial results for 2025. |
| 2025-04-22 16:15:00 | Bristol Myers Squibb Announces Topline Results From Phase 3 Arise Trial Evaluating Cobenfy (xanomeline And Trospium Chloride) As An Adjunctive Treatment To Atypical Antipsychotics In Adults With Schizophrenia Princeton, n.j.--(business wire)---- $bmy #arise--bms announces topline results from phase 3 arise trial. |
| 2025-04-17 20:21:00 | U.s. Food And Drug Administration Updates Camzyos® (mavacamten) Label To Reduce Echocardiography Monitoring Requirements And Contraindications Princeton, n.j.--(business wire)---- $bmy #camzyos--u.s. food and drug administration updates camzyos® (mavacamten) label to reduce echocardiography monitoring requirements and contraindications. |
| 2025-04-16 17:16:00 | 2seventy Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of 2seventy Bio, Inc. - Tsvt New york & new orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of 2seventy bio, inc. (nasdaqgs: tsvt) to bristol myers squibb (nyse: bmy). under the terms of the proposed transaction, shareholders of 2seventy will receive $5.00 in cash for each share of 2seventy that they own. ksf is seeking to determine whether this consideration and the process that led to it ar. |
| 2025-04-14 16:15:00 | Bristol Myers Squibb Provides Update On Phase 3 Odyssey-hcm Trial Princeton, n.j.--(business wire)---- $bmy #camzyos--bristol myers squibb provides update on phase 3 odyssey-hcm trial. |
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Legal